Larimar Therapeutics reports preliminary cash balance of $138.5M as of June 30, 2025

Larimar Therapeutics, Inc.

Preliminary unaudited cash, cash equivalents and marketable securities of $138.5M as of June 30, 2025.
Disclosed in a preliminary prospectus supplement filed under Rule 424(b)(5) on July 29, 2025.
Financial close for Q2 2025 not complete; amount subject to change.

item 2.02

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-168096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.